The problem from a short term perspective is it just isnt a "hype" biostock ala a KSX or SLA.
The balance sheet shows the potential though, annual revenues of $40 million show that there is a valid business here. I think a profit of say, $3 million for FY07 will do the trick if they continue to hard sell the new sleep apnoae treatment. Broker roadshows should be on the agenda after the FY results are released.
Patience, imho this deserves to be trading within a 30-50cps range which would still only give it a market cap of $40 mill to $70 mill. Too cheap at these levels given the fundamentals.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.005(1.79%) |
Mkt cap ! $54.78M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 28.0¢ | $1.46K | 5.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19300 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 20999 | 1 |
View Market Depth
| Last trade - 14.20pm 21/07/2025 (20 minute delay) ? |
| CMP (ASX) Chart |